Search results
Your search for Teclistamabor returned no results
Showing 1 to 14 of 14 results for teclistamab
Showing 1 to 14 of 14 results for teclistamab
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628
In development Reference number: GID-TA11826 Expected publication date: TBC
Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
We are listening to your views on this Technology appraisal guidance. Comments close 29 June 2026.
Evidence-based recommendations on belantamab mafodotin (Blenrep) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
In development Reference number: GID-TA11956 Expected publication date: 28 January 2027
In development Reference number: GID-TA11052 Expected publication date: 17 February 2027
Evidence-based recommendations on belantamab mafodotin (Blenrep) with pomalidomide and dexamethasone for previously treated multiple myeloma in adults.
See a complete list of all our guidance and quality standards currently open for consultation
Awaiting development Reference number: GID-TA11162 Expected publication date: 28 July 2027
Awaiting development Reference number: GID-TA11830 Expected publication date: TBC
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections
This guidance has been updated and replaced by NICE technology appraisal guidance 1015.
Two new treatment options for incurable blood cancer assessed
We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.